Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trastuzumab + docetaxel with or without bevacizumab and trastuzumab + docetaxel + NPLD with or without bevacizumab in HER2-positive early breast cancer
2010-023324-25Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Feb 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trastuzumab, docetaxel, bevacizumab and doxorubicin in breast cancer (4 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Started Feb 2011; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-023324-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023324-25.